Bristol-Myers Squibb defended its planned $74 billion takeover of Celgene Corp, ...
- Bristol-Myers Squibb defended its planned $74 billion takeover of Celgene Corp, saying it had carried out a “robust” assessment of the merger after two major investors opposed what could be the largest pharmaceutical deal ever.
Starboard, an activist investor with a history of opposing deals it is unhappy with, maintained its view on Wednesday that the merger was “ill-advised” and recommended that fellow Bristol-Myers shareholders vote against it at a meeting slated for April 12. “While letter conveys the Board’s belief that the deal is compelling, the intent of the letter also appears to be to address shareholders arguments against the deal,” Credit Suisse analyst Vamil Divan said.
As its most important cancer immunotherapy Opdivo faces competition from Merck & Co’s Keytruda, Bristol-Myers is betting on Celgene to strengthen its position in the lucrative oncology market.
इंडिया ताज़ा खबर, इंडिया मुख्य बातें
Similar News:आप इससे मिलती-जुलती खबरें भी पढ़ सकते हैं जिन्हें हमने अन्य समाचार स्रोतों से एकत्र किया है।
Bristol-Myers tells opponents Celgene deal is 'best path'Bristol-Myers Squibb urged shareholders on Wednesday to support its planned $74 ...
और पढो »
Starboard Details Opposition to Bristol-Myers Deal for CelgeneActivist investor Starboard Value detailed its opposition to Bristol-Myers Squibb’s proposed acquisition of Celgene, describing the proposed takeover as poorly conceived and ill advised.
और पढो »
Top Bristol-Myers shareholder comes out against $74 billion Celgene dealBristol-Myers Squibb Co's top shareholder Wellington Management said on Wed...
और पढो »
Activist investor Starboard Value says it will oppose Bristol-Myers' $74 billion deal for CelgeneActivist investor Starboard Value said that it intends to use its stake in Bristol-Myers Squibb to oppose the drug-maker’s acquisition of Celgene.
और पढो »
Celgene falls 8 percent after Wellington Management says it opposes Bristol-Myers acquisition
और पढो »
Activist investor Starboard Value says it will oppose Bristol-Myers' deal for CelgeneThe activist investor said Thursday that it intends to use its stake in Bristol-Myers Squibb to oppose its acquisition of Celgene.
और पढो »
Bristol-Myers urges shareholders in open letter to support $74 billion Celgene deal amid resistanceThe company said in an open letter to shareholders, its board of directors are 'confident' the drugmakers acquisition of Celgene is the best path forward.
और पढो »
Starboard joins opposition to Bristol-Myers' $74 billion Celgene dealActivist hedge fund Starboard Value LP followed Bristol-Myers Squibb Co's s...
और पढो »
Starboard to vote against Celgene/Bristol deal, move ahead with proxyActivist investor Starboard Value LP plans to vote against Bristol-Myers Squibb ...
और पढो »
Bristol-Myers' record-breaking $74 billion biotech deal is in jeopardyBristol-Myers Squibb Co.'s $74 billion takeover of Celgene is in jeopardy after the former's second-largest shareholder has turned against it.
और पढो »